

Polymorphism in Pharmaceutical Solids

edited by
Harry G. Brittain
Discovery Laboratories, Inc.
Milford, New Jersey



MARCEL DEKKER, INC.

NEW YORK • BASEL

Gilead 2014

36-19870

RS201
857
P64
1999

I.I.T. LIBRARIES
APR 20 2000
RECEIVED

: 0-8247-0237-9

book is printed on acid-free paper.

quarters
el Dekker, Inc.
Madison Avenue, New York, NY 10016
12-696-9000; fax: 212-685-4540

rn Hemisphere Distribution
el Dekker AG
Postfach 812, CH-4001 Basel, Switzerland
4-61-261-8482; fax: 44-61-261-8896

d Wide Web
www.dekker.com

ublisher offers discounts on this book when ordered in bulk quantities. For more
nation, write to Special Sales/Professional Marketing at the headquarters address

right © 1999 by Marcel Dekker, Inc. All Rights Reserved.

er this book nor any part may be reproduced or transmitted in any form or by
means, electronic or mechanical, including photocopying, microfilming, and re-
ing, or by any information storage and retrieval system, without permission in
g from the publisher.

nt printing (last digit):
9 8 7 6 5 4 3 2 1

ITED IN THE UNITED STATES OF AMERICA

Preface

Since the middle of the last century, it has been noted that organic molecules can be obtained in more than one distinct crystal form, a property that became known as polymorphism. Once experimental methods based on the diffraction of x-rays were developed to determine the structures of crystalline substances, it was quickly learned that an extremely large number of molecules were capable of exhibiting the phenomenon. In addition, numerous compounds were shown to form other nonequivalent crystalline structures through the inclusion of solvent molecules in the lattice.

It was also established that the structure adopted by a given compound upon crystallization would exert a profound effect on the solid-state properties of that system. For a given material, the heat capacity, conductivity, volume, density, viscosity, surface tension, diffusivity, crystal hardness, crystal shape and color, refractive index, electrolytic conductivity, melting or sublimation properties, latent heat of fusion, heat of solution, solubility, dissolution rate, enthalpy of transitions, phase diagrams, stability, hygroscopicity, and rates of reactions are all determined primarily by the nature of the crystal structure.

I. Bernstein, *Acta Cryst.*, B35, 360 (1979).
 I. Bar and J. Bernstein, *J. Phys. Chem.*, 86, 3223 (1982).
 I. J. Gerber, M. R. Caira, and A. P. Lötter, *J. Cryst. Spect. Res.*, 23, 863 (1993).
 V. Agafonov, B. Legendre, N. Rodier, D. Wouessidejewe, and J.-M. Cense, *J. Pharm. Sci.*, 80, 181 (1991).
 Y. Hiramatsu, H. Suzuki, A. Kuchiki, H. Nakagawa, and S. Fujii, *J. Pharm. Sci.*, 85, 761 (1996).
 G. A. Stephenson, T. B. Borchardt, S. R. Byrn, J. Bowyer, C. A. Bunnell, S. V. Snorek, and L. Yu, *J. Pharm. Sci.*, 84, 1385 (1995).
 A. Miyamae, S. Koda, S. Kitamura, Y. Okamoto, and Y. Morimoto, *J. Pharm. Sci.*, 79, 189 (1990).
 N. Feeder and W. Jones, *Acta Cryst.*, C50, 816 (1994).
 G. R. Desiraju, *Science*, 278, 404 (1997).

4

Structural Aspects of Hydrates and Solvates

Kenneth R. Morris

Purdue University
 West Lafayette, Indiana

I. PHARMACEUTICAL IMPORTANCE OF CRYSTALLINE HYDRATES	126
II. HYDRATE THERMODYNAMICS	130
A. Classical Higuchi/Grant Treatment	130
B. Similarities and Differences Between Polymorphs and Hydrates	132
C. Hydrogen Bonding in Hydrates	135
III. CLASSIFICATION OF HYDRATES	141
A. Class 1: Isolated Site Hydrates	142
B. Class 2: Channel Hydrates	145
C. Class 3: Ion Associated Hydrates	155
IV. DEHYDRATION/HYDRATION KINETICS	161
A. Dehydration and Hydrate Class	162
B. Impact of Particle Size and Morphology	163

Morris	
BEHAVIOR OF HYDRATES DURING PROCESSING, HANDLING, AND STORAGE	167
A. Processing Induced Transitions	167
B. Transitions in the Final Product	173
C. Kinetics of Transformation	177
SUMMARY	178
REFERENCES	179

HARMACEUTICAL IMPORTANCE OF CRYSTALLINE HYDRATES

potential pharmaceutical impact of changes in hydration state of line drug substances and excipients exists throughout the development process. The behavior of pharmaceutical hydrates has become a subject of increasing attention over the last decade, primarily due to the potential impact of hydrates on the development process and dosage form performance. Substances may hydrate/dehydrate in response to changes in environmental conditions during processing, or over time if in a metastable thermodynamic state. It may not be practical or possible to maintain the same hydrate form at the discovery bench scale synthesis during scale-up activities of a hydrated compound. The choice of counterions to produce a more stable salt form may also be dictated by the extent and type of hydrate observed for a given salt and/or by the moisture level that may be readily accommodated by the dosage form [2].

The physicochemical stability of the compound may raise issues during formulation. Some hydrated compounds may convert to an anhydrous form upon dehydration and some may become chemically unstable. This is true of cephradine dihydrate that dehydrates to become anhydrous and undergoes subsequent oxidation. Other compounds may convert from a lower to a higher state of hydration yielding

Structural Aspects of Hydrates and Solvates


forms with lower solubility. In any case, the resulting "new" forms would represent unique entities that, depending on the dosage form, might have to be maintained throughout the manufacturing process and in the clinic and would impact on the regulatory status of the compound. Most often this demands that the form (usually crystalline) be identified and characterized with respect to handling conditions during the early pre-IND stage of the development process.

As dosage form development proceeds, changes in hydration state can result in variable potencies depending on handling conditions during weighing steps, the kinetics of the hydration/dehydration process, and the environmental conditions during processing. Differences in powder flow can result from changes in crystal form and/or morphology that may accompany the hydration/dehydration process. This can affect content uniformity in solid processing either in the mixing process or during transfer to other processing equipment such as tablet presses. Aqueous granulation, particle size reduction, film coating, and tablet compression all provide opportunities to "trap" a compound in a metastable form that may "relax" to a more stable form at some unpredictable point in the life of a dosage form. Alternately, a kinetically favored but thermodynamically unstable form may be converted during these processes to a more stable and less soluble form.

During and after manufacturing, moisture from the environment or that sealed in the package may redistribute throughout the dosage form and change the hydration state(s). These changes can, in turn, visit the negative consequences discussed above for the bulk drug on the dosage form. These can be manifest as changes in tablet/capsule dissolution rates (and perhaps bioavailability), changes in lyophilic constitution times, tablet capping, chemical instability, discoloration, and more. Of course, the potential for changes in hydration state also exists for many pharmaceutical excipients (such as lactose or magnesium stearate).

Such problems are typically magnified as both synthetic and dosage form production is scaled up. This may be caused by solvent limitations, heat transfer differences in production equipment, changes in raw materials and/or raw material suppliers, changes in processing times, and time and control constraints on product storage, to name a few.

Arguments just provided detail the potential issues around in the development process. The other consideration is the frequency with which hydrates are encountered in real life. Focusing on drug substances, it is estimated that approximately one-third of pharmaceutical actives are capable of forming crystalline hydrates [3]. A search of the Cambridge Structural Database (CSD) shows that approximately 11% of all the reported crystal structures contain water [4]. This represents over 16,000 compounds. If organic compounds are excluded, this number drops to approximately 0.8%, and the breakdown of these according to hydration number is shown in Fig. 1. This shows the expected trend in which monohydrate is most frequently encountered, and where the frequency decreases almost exponentially as the hydration number increases. The hydrate stoichiometry occurs approximately as frequently as the monohydrate, which should serve as a caution to explore fully the occurrence of fractional hydration. That is, an apparent stoichiometry of 0.6 molecules could be a partially dehydrated monohydrate, or it



Occurrence of various crystalline hydrate stoichiometries.

could be a hemihydrate with additional sorption due to defects or amorphous material.

The symmetry of these hydrate crystals follows fairly closely with that reported for organic structures overall [5]. Table 1 shows the breakdown for space groups, organized by crystal system, accounting for the top approximately 90% of the structures. $P_{21/c}$ (number 14) is the most common space group here as with the general population of organic molecules contained in the CSD. It has been reported for inorganic species that hydrated structures are generally of lower symmetry than are their anhydrous counterparts [6]. This is attributed to the fact that the highest symmetry associated with the water molecule is C_{2v} and most inorganic structures are of higher symmetry. This is not obviously the case for organic structures. Regardless of the solvation state, organic molecules generally exhibit lower symmetry than do inorganic compounds, so the impact of the symmetry constraints imposed by water does not appear to be the controlling element. Further comparisons would be required to explore the phenomena fully.

Table 1 Space Groups for the Top 90% of Organic Crystalline Hydrates in the Cambridge Structural Database

Space group	Crystal system	Percent occurrence
P_{-1}	Triclinic	15.5
P_1	Triclinic	2.6
$P_{21/c}$	Monoclinic	23.2
P_{21}	Monoclinic	13.4
$C_{2/e1}$	Monoclinic	5.8
C_2	Monoclinic	2.8
P_{212121}	Orthorhombic	17.8
P_{bca}	Orthorhombic	2.3
P_{21212}	Orthorhombic	1.8
P_{nca21}	Orthorhombic	1.8
P_{nma}	Orthorhombic	1.3
Unknown		1.2